Fesoterodine
- Generic Name
- Fesoterodine
- Brand Names
- Toviaz
- Drug Type
- Small Molecule
- Chemical Formula
- C26H37NO3
- CAS Number
- 286930-02-7
- Unique Ingredient Identifier
- 621G617227
- Background
Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome.
- Indication
适用于治疗急迫性尿失禁和膀胱过度活动综合征患者的尿频、尿急、尿失禁或所有这些症状组合。
- Associated Conditions
- Neurogenic Detrusor Overactivity, Overactive Bladder Syndrome (OABS)
A Study of Fesoterodine and Oxybutynin on Cognitive Function in Mild Cognitive Impairment
- Conditions
- Overactive BladderMild Cognitive Impairment
- Interventions
- First Posted Date
- 2014-09-15
- Last Posted Date
- 2020-02-19
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 47
- Registration Number
- NCT02240459
- Locations
- 🇨🇦
Division of Geriatric Medicine, Clinical Sciences Building, University of Alberta Hosp, Edmonton, Alberta, Canada
Study to Estimate the Relative Bioavailability Compared to Commercial Extended-release Tablet Formulation and the Effects of Food Or Sprinkling on Applesauce for Fesoterodine Sustained-release Beads-in-capsule Formulations in Healthy Adult Volunteers
- First Posted Date
- 2014-06-10
- Last Posted Date
- 2015-01-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT02160158
- Locations
- 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium
Drug Use Investigation for Toviaz
- First Posted Date
- 2013-09-06
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 2521
- Registration Number
- NCT01936870
Validation of Instruments for Pragmatic Clinical Trials for Overactive Bladder
- First Posted Date
- 2013-08-19
- Last Posted Date
- 2014-12-10
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 75
- Registration Number
- NCT01925456
- Locations
- 🇺🇸
University of Pennsylvania 3400 Spruce Street-1000 Courtyard, Philadelphia, Pennsylvania, United States
Understanding the Response to Fesoterodine Through Genetic Evaluation in the Elderly (URGE)
- First Posted Date
- 2013-02-08
- Last Posted Date
- 2020-03-18
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 61
- Registration Number
- NCT01786967
- Locations
- 🇺🇸
UNC-Chapel Hill, Dept of Ob/Gyn, Chapel Hill, North Carolina, United States
A Study of Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Lap. Prostatectomy
- Conditions
- Prostate Adenocarcinoma
- Interventions
- Drug: Placebo oral tablet
- First Posted Date
- 2012-08-09
- Last Posted Date
- 2020-04-28
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 3
- Registration Number
- NCT01661166
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Premarin Versus Toviaz for Treatment of Overactive Bladder
- First Posted Date
- 2012-06-07
- Last Posted Date
- 2017-04-20
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 90
- Registration Number
- NCT01613170
- Locations
- 🇺🇸
Cleveland Clinic Florida, Weston, Florida, United States
Trial of Percutaneous Tibial Nerve Stimulation (PTNS) Versus PTNS and Fesoterodine Fumarate
- Conditions
- Overactive Bladder
- Interventions
- First Posted Date
- 2012-05-25
- Last Posted Date
- 2014-02-05
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 4
- Registration Number
- NCT01605617
- Locations
- 🇺🇸
Mayo Clinic in Arizona (MCSB and MCH), Phoenix, Arizona, United States
Solifenacin Succinate Versus Fesoterodine A Comparison Trial for Urgency Symptoms
- Conditions
- Urinary Bladder, Overactive
- Interventions
- First Posted Date
- 2012-05-09
- Last Posted Date
- 2012-05-16
- Lead Sponsor
- Rambam Health Care Campus
- Target Recruit Count
- 60
- Registration Number
- NCT01595152
- Locations
- 🇮🇱
Rambam Health Care Campus, Haifa, Israel
🇮🇱Belinson, Petach Tikva, Israel
🇮🇱Asaf harofeh, Tel Aviv, Israel
Comparison of Efficacy and Safety Between Imidafenacin and Fesoterodine in Patients With Overactive Bladder
- First Posted Date
- 2012-04-16
- Last Posted Date
- 2012-04-16
- Lead Sponsor
- LG Life Sciences
- Target Recruit Count
- 207
- Registration Number
- NCT01578304
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.